Squarepoint
KROS icon

Squarepoint’s Keros Therapeutics KROS Stock Holding History

Squarepoint’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$334K Buy
+31,204
New +$348K ﹤0.01% 3726
2025
Q4 		– Sell
-100,141
Closed -$1.58M – 4592
2025
Q3 		$1.58M Buy
+100,141
New +$1.48M ﹤0.01% 2290
2025
Q2 		– Sell
-43,984
Closed -$448K – 4783
2025
Q1 		$448K Buy
+43,984
New +$511K ﹤0.01% 3407
2024
Q4 		– Sell
-4,525
Closed -$263K – 5288
2024
Q3 		$263K Sell
4,525
-15,307
-77% -$756K ﹤0.01% 3539
2024
Q2 		$906K Buy
+19,832
New +$1.07M ﹤0.01% 2634
2022
Q4 		– Sell
-19,919
Closed -$749K – 3423
2022
Q3 		$749K Buy
19,919
+2,204
+12% +$76.4K ﹤0.01% 1957
2022
Q2 		$489K Buy
+17,715
New +$777K ﹤0.01% 2026
2021
Q1 		– Sell
-9,035
Closed -$637K – 3373
2020
Q4 		$637K Buy
+9,035
New +$569K ﹤0.01% 1626

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Squarepoint's KROS Position: Q2 2026 in Review

Squarepoint opened a new position in Keros Therapeutics (KROS) in Q2 2026: 31,204 shares worth $334K. The stake represents ﹤0.01% of the portfolio and ranks #3726 among its holdings. This is a return to the name: Squarepoint previously reported a position in KROS as recently as Q3 2025.

Squarepoint first reported a position in KROS in Q4 2020 and has held it in 8 quarters since. The position peaked at $1.58M in Q3 2025. 133 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Squarepoint held 31,204 shares of Keros Therapeutics worth $334K as of Q2 2026.
  • Keros Therapeutics was a new Squarepoint position in Q2 2026.
  • Keros Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3726 holding.
  • Squarepoint first reported a position in Keros Therapeutics in Q4 2020 and has held it in 8 quarters since.
  • Squarepoint's Keros Therapeutics position peaked at $1.58M in Q3 2025.
  • 133 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.